Stock OSL ONCOSIL MEDICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

OncoSil Medical Limited Share Price

Equities

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E.
Other stock markets
 11:26:36 29/04/2024 am IST 		5-day change 1st Jan Change
0.005 AUD +25.00% Intraday chart for OncoSil Medical Limited -16.67% -44.44%
18/04 OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial MT
16/04 OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device MT

Financials

Sales 2022 1.06M 699K 58.24M Sales 2023 1.47M 964K 80.37M Capitalization 23.71M 15.57M 1.3B
Net income 2022 -10M -6.57M -548M Net income 2023 -11M -7.23M -602M EV / Sales 2022 27 x
Net cash position 2022 10.98M 7.21M 601M Net cash position 2023 9.22M 6.06M 505M EV / Sales 2023 9.87 x
P/E ratio 2022
-3.02 x
P/E ratio 2023
-1.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 55.27%
More Fundamentals * Assessed data

Chart OncoSil Medical Limited

Dynamic Chart

Latest news about OncoSil Medical Limited

OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial MT
OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device MT
OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study MT
OncoSil Medical Obtains Device Reimbursement Approval in UK MT
First Austria-Based Patients Treated Using OncoSil Pancreatic Cancer Device MT
Oncosil Medical Issues Non-Renounceable Entitlement Offer Prospectus MT
Oncosil Medical to Raise Over AU$7 Million via Placement, Entitlement Offer MT
OncoSil Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Australian Shares End Eight-Day Winning Streak as Early US Fed Rate Cut Hopes Fade MT
OncoSil Device Included in German Funding Program Negotiations; Shares Jump 14% MT
OncoSil Strikes Exclusive Distribution Deal For Turkish Market; Shares Jump 14% MT
OncoSil Medical Receives AU$1.1 Million R&D Tax Rebate MT
First Patient Treated in OncoSil Medical's Pancreatic Cancer Drug Trial MT
Oncosil Medical Limited Elects Gabrielle Liberatore as Director CI
Australian Shares Rise on Expectations of Easing October CPI MT
More news

Analyst Recommendations on OncoSil Medical Limited

Oncosil Medical Issues Non-Renounceable Entitlement Offer Prospectus MT
Australian Shares End Eight-Day Winning Streak as Early US Fed Rate Cut Hopes Fade MT
Oncosil Medical Limited Reports Preliminary Consolidated and Company Earnings Results for the Year Ended June 30, 2013 CI
More recommendations

Press releases OncoSil Medical Limited

OncoSil Medical : Application for quotation of securities - OSL PU
OncoSil Medical : Application for quotation of securities - OSL PU
OncoSil Medical : Clarification Of Non-Renouncable Entitlement Offer Details PU
OncoSil Medical : Appoints Global Sales and Marketing Director PU
Oncosil Medical : $10 Million Institutional Placement PU
More press releases

Quotes and Performance

1 day+25.00%
1 week-16.67%
1 month-16.67%
3 months-28.57%
6 months-44.44%
Current year-44.44%
More quotes

Highs and lows

1 week
0.00
Extreme 0.004
0.01
1 month
0.00
Extreme 0.004
0.01
Current year
0.00
Extreme 0.004
0.01
1 year
0.00
Extreme 0.004
0.02
3 years
0.00
Extreme 0.004
0.11
5 years
0.00
Extreme 0.004
0.22
10 years
0.00
Extreme 0.004
0.28
More quotes

Managers and Directors - OncoSil Medical Limited

Managers TitleAgeSince
Nigel Lange CEO
 Chief Executive Officer - 04/20/04
Christian Cin DFI
 Director of Finance/CFO - 01/23/01
Jon Bell CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Nigel Lange CEO
 Chief Executive Officer - 04/20/04
Douglas Cubbin CHM
 Chairman - 07/23/07
Gabriel Liberatore BRD
 Director/Board Member - 14/23/14
More insiders

Quotes

Date Price Change Volume
29/24/29 0.005 +25.00% 2 075 022
26/24/26 0.004 -20.00% 1,144,912
24/24/24 0.005 +25.00% 4,890,014
23/24/23 0.004 -33.33% 14,780,500
22/24/22 0.006 0.00% 134,070

Delayed Quote Australian S.E., April 29, 2024 at 11:26 am IST

More quotes

Company Profile

OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient’s pancreatic tumors through an endoscopic ultrasound. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous-32 microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.
Sector
Pharmaceuticals
Calendar
22/08/2024 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ONCOSIL MEDICAL LIMITED Stock OncoSil Medical Limited
-44.44% 5.88M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.57% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.75% 231B
NOVARTIS AG Stock Novartis AG
+5.24% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-8.75% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. OSL Stock